CD8A and neoplasm: Next, we performed a similar experiment in a competitive setting, wherein CD45.1+CD45.2+ KCa.3.1WT and CD45.1+ KCa.3.1R350A-expressing OT-I CD8+ T cells were mixed at a 1:1 ratio and transferred into B16-OVA tumor-bearing Rag1−/− mice (Fig. 6a).